Drug intelligence / Profile preview

bevacizumab + cyclophosphamide + doxorubicin + paclitaxel

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

This combination involves **bevacizumab**, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), preventing tumor angiogenesis; **cyclophosphamide**, an alkylating agent that interferes with DNA replication; **doxorubicin**, an anthracycline antibiotic that intercalates DNA strands; and **paclitaxel**, a taxane that stabilizes microtubules, preventing cell division. This combination is not a standard approved regimen but could be used in experimental or clinical trial settings for various cancers.

Targets

MicrotubuleVEGFA (Vascular endothelial growth factor A)DNA

Beyond the preview

Go deeper on bevacizumab + cyclophosphamide + doxorubicin + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + cyclophosphamide + doxorubicin + paclitaxel.

Explore the full profile